

ORIGINAL ARTICLE

Quality of life in caregivers of children with asthma: Validity and reliability of the IFABI-R questionnaire



A. Cano-Garcinuño^{a,*}, D. Forns-Serrallonga^b, I. Mora-Gandarillas^c, A. Bercedo-Sanz^d,
M.T. Callén-Blecua^e, J.A. Castillo-Laita^f, I. Casares-Alonso^g, E. Tauler-Toro^h,
L.M. Alonso-Bernardoⁱ, Á. García-Merino^j, I. Moneo-Hernández^k, O. Cortés-Rico^l,
I. Carvajal-Urueñaⁱ, J.J. Morell-Bernabé^m, I. Martín-Ibáñezⁿ,
C.R. Rodríguez-Fernández-Oliva^o, M.T. Asensi-Monzó^p, C. Fernández-Carazo^q,
J. Murcia-García^r, C. Durán-Iglesias^s, J.L. Montón-Álvarez^t,
B. Domínguez-Aurrecoechea^u, M. Praena-Crespo^v

^a CS Villamuriel de Cerrato, Palencia, Spain

^b Department of Clinical Psychology and Health, Barcelona Autonomous University, Barcelona, Spain

^c CS Infiesto, Asturias, Spain

^d CS Buelna, Santander, Spain

^e CS Bidebieta, San Sebastián, Spain

^f CS Fuentes de Ebro, Zaragoza, Spain

^g CS Venta de Baños, Palencia, Spain

^h ABS Martorell, Barcelona, Spain

ⁱ CS La Ería, Oviedo, Spain

^j CS Vallobín-La Florida, Oviedo, Spain

^k CS Las Fuentes Norte, Zaragoza, Spain

^l CS Canillejas, Madrid, Spain

^m CS Zona Centro, Badajoz, Spain

ⁿ CAP La Mina, Barcelona, Spain

^o CS La Cuesta, Tenerife, Spain

^p CS Serrería, Valencia, Spain

^q CS El Valle, Jaén, Spain

^r CS San Felipe, Jaén, Spain

^s CS Arroyo de la Luz, Cáceres, Spain

^t CS Mar Báltico, Madrid, Spain

^u CS Otero, Oviedo, Spain

^v CS La Candelaria, Sevilla, Spain

Received 1 February 2015; accepted 29 April 2015

Available online 1 August 2015

* Corresponding author.

E-mail address: acanog@saludcastillayleon.es (A. Cano-Garcinuño).

KEYWORDS

Asthma;
Quality of life;
Caregivers;
Family impact

Abstract

Background: Parents'/caregivers' quality of life is an important aspect to consider when handling paediatric asthma, but there is a paucity of valid and reliable instruments to measure it. The Family Impact of Childhood Bronchial Asthma (IFABI-R) is a recently developed questionnaire to facilitate the assessment of asthma-related parents'/caregivers' quality of life. This study researches the psychometric properties of IFABI-R.

Methods: Parents/main caregivers of 462 children between 4 and 14 years of age with active asthma were included in the sample. IFABI-R was administered on two different occasions and a number of other variables related to the parents'/caregivers' quality of life were measured: child's asthma control, family functioning, and parents'/caregivers' perception of asthma symptoms in the child. IFABI-R evaluative and discriminative properties were analysed, and the minimal important change in the IFABI-R score was identified.

Results: IFABI-R showed high internal consistency (Cronbach's $\alpha = 0.941$), cross-sectional construct validity (correlation with the degree of child's asthma control, family functioning and parent/caregiver perception of the child's asthma symptoms), longitudinal construct validity (correlation of changes in the IFABI-R with changes in asthma control and changes in the perception of symptoms), sensitivity to change and test-retest reliability. An absolute change of 0.3 units in IFABI-R related to a minimal significant change in the parents'/caregivers' quality of life.

Conclusions: IFABI-R is a reliable and valid instrument to study the quality of life of parents/caregivers of children with asthma.

© 2015 SEICAP. Published by Elsevier España, S.L.U. All rights reserved.

Introduction

Asthma is a chronic disease with a high prevalence in children: worldwide, 12–14% of school children and adolescents refer to having had recent asthma symptoms, according to the third phase of the International Study of Asthma and Allergies in Childhood¹; similar figures have been observed in Spain.² The current clinical guidelines for the management of patients with asthma establish that the therapeutic objective is to control the disease.^{3,4} This control has a clinical-based definition: symptoms, limitation of daily activities, need for rescue bronchodilators and alterations in pulmonary function tests. Numerous clinical trials have proven the effectiveness of the available medication to adequately control the disease; nevertheless, many children and adolescents with asthma have an insufficient degree of control.

Asthma affects patients' quality of life, which is worse when the disease is not sufficiently controlled.⁵ However, the impact of asthma also affects the child's parents and caregivers, whose quality of life is closely linked to the degree to which the disease is controlled.⁶ This impact of asthma on the parents'/caregivers' quality of life has attracted growing interest in research, as certain critical aspects of asthma management in children (such as therapeutic adherence) are closely linked to the way in which parents/caregivers perceive the burden of the disease on the child and themselves.^{7,8} Therefore, measuring the parents'/caregivers' quality of life is important, both for research as well as for the clinical practice.

Measuring the quality of life of the parents'/caregivers' of children with asthma requires having valid and reliable instruments. Until recently, there was only one specifically designed instrument: the *Pediatric Asthma Caregiver's*

Quality of Life Questionnaire (PACQLQ).⁹ This instrument has been widely used in the literature since it was first published almost two decades ago; it has also been adapted to a variety of languages. There is a Spanish-language version that is used extensively in Spain and South America, but it has not been formally validated until now. Moreover, PACQLQ only researches two of the parents/caregivers' quality of life spheres: physical-functional and emotional; its factorial structure lacks a specific domain that analyses the repercussion of childhood asthma in the social and labour life of their parents/caregivers, which is an extremely important aspect when evaluating quality of life.

In an effort to solve these limitations, a new instrument was recently developed to assess the quality of life of the parents/caregivers of children with asthma: the *Family Impact of Childhood Bronchial Asthma-Revised* (IFABI-R).¹⁰ Developed and validated in Spanish, this new instrument has proven to have an adequate factorial structure to assess the three main dimensions for the quality of life in parents/caregivers of children with asthma: the functional, emotional and socio-occupational dimensions. The initial study showed that the IFABI-R has an elevated internal consistency and construct validity verified by its cross-sectional correlation with measures of asthma severity, morbidity and the parents'/caregivers' perception of symptoms.¹⁰ Moreover, the IFABI-R is currently being used successfully in clinical studies.⁶

However, it is essential to improve our knowledge of the psychometric properties of IFABI-R before it continues to be used clinically. Certain characteristics of this instrument—relating to validity, reliability and sensitivity to change—need to be defined further. The objective of this study is to expand the knowledge of the metric qualities of IFABI-R, through a new validation of the instrument.

Methods

Sample

At 22 primary care centres in Spain, the main caregivers of 4–14-year-old children with asthma were recruited. For inclusion, asthma had to have been diagnosed by a doctor and have shown symptoms within the previous 12 months. The accompanying adult identified him/herself as the child's main caregiver. Caregivers, who, in the opinion of the researchers, had a limited command of the Spanish language were excluded. The study was approved by the Ethical Committee at the centre coordinating the project (Palencia Healthcare Area, Spain) and the participants, both parents/caregivers as well as children granted written permission to take part in the study.

Variables

The variables of the study were obtained through questionnaires filled out by the caregiver as well as by reviewing the patients' clinical history. The variables measured were:

- (1) The parents'/caregivers' quality of life was studied using the *Family Impact of Childhood Bronchial Asthma-Revised* (IFABI-R),¹⁰ available after permission request in www.bibliopro.org. It is an assessment instrument that measures the quality of life during the three previous months and is specific for caregivers of children with asthma. It was developed in Spanish, and consists of 15 items that offer four response options each. Responses assign a higher score when the caregivers' quality of life is worse. The instrument has been proven to have an adequate factorial structure to explore three quality of life dimensions: functional, emotional and socio-occupational. Four variables were obtained to be used in the analysis: total instrument score (IFABI-T), and the scores for each of the sub-scales: functional (IFABI-F), emotional (IFABI-E) and socio-occupational (IFABI-S). All scores ranged between 1 (better) and 4 (worse quality of life). Only fully completed questionnaires were included in the analyses.
- (2) Caregiver's perception of asthma symptoms was evaluated using the Spanish-language version^{11,12} of the questionnaire on the perception of symptoms and incapacity in asthma (PSI) by Usherwood et al.¹³ This questionnaire explores the perception that parents/caregivers have of the symptoms and incapacity due to their child's asthma in the past three months. It consists of 17 items with five response options each and includes three dimensions: daytime symptoms, night-time symptoms and incapacity. The reliability and validity of the Spanish-language version has been verified in caregivers of children between 2 and 15 years old. The mean scores for the complete instrument (PSI-T) were obtained as well as for each of the subscales: daytime symptoms (PSI-D), night-time symptoms (PSI-N) and incapacity due to asthma (PSI-I), all on a scale between zero (lesser intensity of symptoms) and 4 (greater intensity).
- (3) Family functioning was assessed using the "family APGAR" instrument by Smilkenstein,¹⁴ which has a validated version in Spanish.¹⁵ "APGAR" is the acronym for family functioning components that the instrument researches (adaptability, partnership, growth, affection and resolve). This self-administrated questionnaire has five items with three possible response options. The scores obtained vary between 1 (worse) and 3 (better family function). All results were categorised as good family functioning (score = 3) or poor family functioning (score < 3).
- (4) Asthma Control was assessed by an experienced paediatrician, based on clinical criteria (Third National Asthma Expert Panel Report, NAEPP-3).³ To assess asthma control in children >6 years of age, pulmonary function was included, which was studied by means of spirometry in keeping with the recommendations of the American Thoracic Society and the European Respiratory Society,¹⁶ using the reference values proposed by the Global Lung Function Initiative.¹⁷ Asthma control was classified on three levels: good, partial and poorly controlled.
- (5) Caregivers' assessment of changes in their quality of life between two evaluations. The *global rating of change* index (GRC) was used, which is a procedure employed in other assessment studies⁹; it uses a 15-point scale of change, between -7 (severe worsening of quality of life) and +7 (huge improvement). When the caregivers indicated a change between -1 and +1, it was considered not to be any change. A score of -3, -2, +2 or +3 was considered a *minimal significant change* in the caregivers' quality of life.

Procedure

During a first study visit, the inclusion criteria were verified, socio-demographic data were collected and the caregiver's quality of life, perception of symptoms and incapacity, family functioning and control of asthma were assessed. During a second visit, 16 weeks later, a new assessment of the caregivers' quality of life, perception of the symptoms and control of asthma was performed, and the *global rating of change* index was also determined.

Analysis

This study sought to include all important metric characteristics in an instrument intended to assess the quality of life, covering both the evaluative properties (which grant the capacity to detect important within-subject changes) such as discriminative properties (ability to detect between-subject differences). To study each of these properties, specific sub-groups from the sample were used (Fig. 1).

In the full sample (*sample A*), the internal consistency was analysed (Cronbach's alpha) as well as the cross-sectional construct validity. This latter was studied using the association of the IFABI-R scores with the PSI (Spearman correlation) and with the degree of asthma control and with family functioning (using variance analysis).

Sub-sample B (patients who came to a second visit, with the same caregiver providing information on both visits) was used to study the longitudinal construct




Figure 1 Sub-samples used in the various sections of the analysis. (A) Total sample ($n = 462$). (B) Sub-sample with data from the second visit ($n = 401$). (C) Sub-sample with change in quality of life between visits 1 and 2 (Global Rating of Change, GRC, outside the range -1 to $+1$) ($n = 269$). (D) Sub-sample with minimal significant change in quality of life between visits 1 and 2 (GRC of -3 , -2 , $+2$ or $+3$) ($n = 49$). (E) Sub-sample without change in the quality of life between visits 1 and 2 (GRC between -1 and $+1$) ($n = 148$). (F) Sub-sample with strict definition of quality of life stability between visits 1 and 2 (see text) ($n = 47$).

validity, analysing the correlation (Spearman coefficient) of the changes observed in the IFABI-R scores with the corresponding changes in the PSI scores and changes in the degree of asthma control.

In *sub-sample C* (caregivers who had a GRC outside the range -1 to $+1$, that is, who referred to significant changes in their asthma-related quality of life), the sensitivity to change of IFABI-R was studied by analysing the differences in the initial and final scores using paired t -tests. Moreover, we studied whether the change in the IFABI-R scores (in absolute values) between the first and second visits differed among those caregivers with a change in their asthma-related quality of life and those without any significant change (*sub-sample C* vs. *sub-sample E*), analysing the differences using unpaired t -tests. Finally, the correlation between changes in IFABI-R with the corresponding score for changes in GRC was studied using Spearman correlation coefficient.

In *sub-sample D* (caregivers who experienced a *minimal significant change* in their quality of life, that is, who had a GRC of -3 , -2 , $+2$ or $+3$) a *minimal important*

difference was identified in the IFABI-R score as the median of the change (in absolute values) taking place in that group. This is similar to the procedure applied in the validation of similar instruments.⁹

Finally, the test-retest stability of IFABI-R scores between the first and second visits were determined using single measure intra-class correlation coefficients based on a one-way random model.¹⁸ Given that the time between the two visits was too prolonged to accept complete stability in all of *sub-sample E* (see Fig. 1), the test-retest stability was studied in the sub-sample of caregivers who complied with a set of strict criteria (*sub-sample F*): absence of important changes in the asthma-related caregivers' quality of life (GRC score between -1 and $+1$), variation in the PSI score (total and for each of its scales) <1 standard deviation of the initial score, lack of change in the degree of asthma control and lack of major family changes during that period (death, divorce, etc.).

The statistically analysis was performed using SPSS 15.0.

Results

Initially, the main caregivers of 510 children were included; of these, 462 completed the IFABI-R correctly on the first visit. Those children not included had no significant differences with respect to sex, age, years with asthma, degree of asthma control, sensitivity to inhalants, season of evaluation, type of maintenance treatment, educational level in the family, family functioning or age of the parents. The most important demographic information is shown in Table 1.

Internal consistency

Cronbach's alpha (95% confidence interval) for the whole instrument was 0.941(0.931–0.950), 0.905 (0.889–0.919) for the functional subscale, 0.883 (0.866–0.899) for the emotional subscale, and 0.883 (0.863–0.902) for the socio-occupational subscale.

Cross-sectional construct validity

Table 2 shows the correlation coefficients between IFABI-R and PSI scores and the association of the IFABI-R scores with the degree of asthma control and family adjustment.

Longitudinal construct validity

Sub-sample B included the caregivers of 401 children (64.1% males) with a mean age (standard deviation, SD) of 9.52 (2.83) years. The correlation coefficients of changes in the IFABI-R and changes in asthma control and PSI scores are shown in Table 3.

Sensitivity to change

Sub-sample C included the caregivers of 269 children (62.8% males) with a mean age (SD) of 9.32 years (2.89). The differences between the initial and final IFABI-R scores were significant ($p < 0.001$) and are shown in Table 4. Sub-sample

Table 1 Characteristics of the sample.

Variable	N	Value
Males (%)	462	63.4
Age, years (mean, SD)	462	9.4 (2.8)
Years with asthma (mean, SD)	457	4.8 (3.0)
Sensitivity to inhalants (%)	439	85.0
Degree of asthma control (%)	462	
Good		53.5
Partial		35.3
Poor		11.3
Hospitalisation in the previous 12 months (%)	456	3.7
Crisis in the previous month (%)	458	32.3
Two or more crises in the previous 12 months (%)	460	12.2
Maintenance treatment (%)	459	
None		35.3
Inhaled corticoids (IC)		42.7
Anti-leukotrienes (AL)		4.8
IC + LABA		9.4
IC + AL		4.8
IC + LABA + AL		3.1
Age of mother, years (mean, DE)	451	39.8 (5.5)
Age of father, years (mean, DE)	436	42.4 (6.3)
Response mother (%)	462	88.7
Educational level in the family (%)	448	
No grade school		2.9
Primary education		39.3
High school		45.3
University		12.5
Poor family functioning (%)	462	39.6
Season when assessment was performed (%)	462	
Spring		62.3
Summer		13.4
Autumn		13.0
Winter		11.3
IFABI-R score (mean, SD)	462	
IFABI-F		1.74 (0.77)
IFABI-E		1.67 (0.73)
IFABI-S		1.40 (0.53)
IFABI-T		1.57 (0.58)

SD, standard deviation; LABA, long-acting beta-adrenergic; IFABI-F, functional sub-scale for IFABI-R; IFABI-E, emotional sub-scale for IFABI-R; IFABI-S, socio-occupational sub-scale for IFABI-R; IFABI-T, total IFABI-R score.

E included 148 children (65.5% males) with a mean age (SD) of 9.74 (2.71) years. Changes (mean, SD) in the absolute value of IFABI-R scores between the two visits were compared for sub-samples C and E. These were: IFABI-T 0.30 (0.29) vs. 0.24 (0.29), $p=0.050$; IFABI-F 0.48 (0.51) vs. 0.41 (0.42), $p=0.167$; IFABI-E 0.37 (0.39) vs. 0.27 (0.35), $p=0.011$; IFABI-S 0.26 (0.32) vs. 0.21 (0.31), $p=0.135$. The correlation coefficients between changes in IFABI-R scores and GRC were: IFABI-T = -0.153 ($p=0.002$); IFABI-F = -0.154 ($p=0.002$); IFABI-E = -0.114 ($p=0.023$); IFABI-S = -0.065 ($p=0.193$).

Minimal important change

Sub-sample D included the caregivers of 49 children (61.2% males) with a mean age (SD) of 8.98 (2.84) years. The absolute value of the IFABI-R scores changes between the first

and second visit (median) was 0.27 for IFABI-T, 0.33 for IFABI-F, 0.20 for IFABI-E and 0.20 for IFABI-S.

Test-retest stability

Sub-sample F included the caregivers of 47 children (66% males) with a mean age (SD) of 9.95 (2.52) years. The inter-class correlation coefficient (95% confidence interval) was 0.929 for IFABI-T (0.877–0.960, $p<0.001$), 0.834 for IFABI-F (0.722–0.904, $p<0.001$), 0.928 for IFABI-E (0.874–0.959, $p<0.001$) and 0.893 for IFABI-S (0.817–0.939, $p<0.001$).

Discussion

This study has confirmed certain properties of the IFABI-R that were described before in the initial study, and has

Table 2 IFABI-R discriminative capacity: cross-sectional construct validity.

	IFABI-F	IFABI-E	IFABI-S	IFABI-T
<i>PSI scores</i>				
PSI-D	0.649 [#]	0.525 [#]	0.474 [#]	0.623 [#]
PSI-N	0.771 [#]	0.581 [#]	0.521 [#]	0.702 [#]
PSI-I	0.720 [#]	0.664 [#]	0.705 [#]	0.770 [#]
PSI-T	0.800 [#]	0.670 [#]	0.654 [#]	0.794 [#]
<i>Degree of asthma control</i>				
Good (n = 247)	1.48 (0.66) [*]	1.50 (0.65) [*]	1.27 (0.45) [*]	1.40 (0.50) [*]
Partial (n = 163)	1.96 (0.74) [*]	1.82 (0.76) [*]	1.52 (0.56) [*]	1.72 (0.59) [*]
Poor (n = 52)	2.24 (0.90) [*]	2.02 (0.79) [*]	1.61 (0.60) [*]	1.88 (0.64) [*]
<i>Family functioning</i>				
Good (n = 279)	1.62 (0.71) [*]	1.52 (0.64) [*]	1.26 (0.38) [*]	1.43 (0.47) [*]
Poor (n = 183)	1.92 (0.83) [*]	1.91 (0.80) [*]	1.61 (0.64) [*]	1.78 (0.67) [*]

IFABI-F, functional sub-scale for IFABI-R; IFABI-E, emotional sub-scale for IFABI-R; IFABI-S, socio-occupational sub-scale for IFABI-R; IFABI-T, total IFABI-R score; PSI, questionnaire about perception of symptoms and incapacity in asthma; PSI-D, PSI sub-scale for daytime symptoms; PSI-N, PSI sub-scale for night-time symptoms; PSI-I, PSI sub-scale for incapacity due to asthma; PSI-T, total PSI score.

[#] Spearman rank correlation coefficient.

^{*} Mean (standard deviation) of the IFABI-R scores in each situation, contrast using variance analysis.

All contrasts in the table are significant ($p < 0.001$).

expanded information regarding other metric qualities for aspects that had not been studied previously. These results prove the validity, reliability and responsiveness of the IFABI-R instrument, which seems adequate to assess the quality of life of caregivers of children with asthma.

An instrument with evaluative capacity must be able to show the changes that come about in each subject (sensitivity to change) and have adequate longitudinal construct validity, proving that the changes observed with the instrument are simultaneous with the changes found in other related constructs. IFABI-R meets all of these requirements.

In-depth observation of the behaviour of each sub-scale for IFABI-R shows that the evaluative performance of the socio-occupational sub-scale is weaker than the other two sub-scales; obvious differences were observed between the initial and final measures when there was a change in the quality of life, but the changes observed in IFABI-S fail to have a good correlation with a global rate of change index and these were not clearly different among the subjects with stable quality of life and those whose quality of life changed.

An instrument with a good discriminative capacity must offer adequate reliability, proven by means of test-retest

Table 3 IFABI-R evaluative capacity: longitudinal construct validity.

	Change in IFABI-F	Change in IFABI-E	Change in IFABI-S	Change in IFABI-T
Change in asthma control	0.227	0.226	0.183	0.238
Change in PSI-T	0.547	0.446	0.447	0.598
Change in PSI-D	0.424	0.359	0.297	0.454
Change in PSI-N	0.537	0.352	0.345	0.506
Change in PSI-I	0.410	0.336	0.456	0.477

IFABI-F, functional sub-scale for IFABI-R; IFABI-E, emotional sub-scale for IFABI-R; IFABI-S, socio-occupational sub-scale for IFABI-R; IFABI-T, total IFABI-R score; PSI, questionnaire about perception of symptoms and incapacity in asthma; PSI-D, PSI sub-scale for daytime symptoms; PSI-N, PSI sub-scale for night-time symptoms; PSI-I, PSI sub-scale for incapacity due to asthma; PSI-T, total PSI score.

The statistics are Spearman rank correlation coefficient (ρ). All contrasts are significant ($p < 0.001$).

Table 4 IFABI-R evaluative capacity: sensitivity to change.

IFABI-R dimensions	Initial score Mean (SD)	Final score Mean (SD)	p (paired t -test)
IFABI-T	1.60 (0.04)	1.46 (0.03)	<0.001
IFABI-F	1.78 (0.05)	1.57 (0.04)	<0.001
IFABI-E	1.72 (0.04)	1.57 (0.04)	<0.001
IFABI-S	1.42 (0.03)	1.33 (0.03)	<0.001

IFABI-F, functional sub-scale for IFABI-R; IFABI-E, emotional sub-scale for IFABI-R; IFABI-S, socio-occupational sub-scale for IFABI-R; IFABI-T, total IFABI-R score; SD, standard deviation.

stability, and have good cross-sectional construct validity. All of these characteristics have been proven in this study, both for the global assessment for IFABI-R as well as for each of the sub-scales.

From the analysis performed, a change of more than 0.3 points in the global IFABI-R score and the sub-scales scores seems to be the best cut-off to identify a minimal important change in the quality of life of caregivers of children with asthma. Although other studies have chosen the mean of the change observed as the cut-off point to identify a minimal important change,⁹ we have used the median because it is a statistic that makes better sense in samples with non-normal distribution.

The main limitation of this work lies in the difficulty to guarantee stability in the caregivers' quality of life when studied 16 weeks apart, and this makes it difficult to verify test-retest stability. To overcome this limitation, the analysis has been limited to the test-retest stability for a sub-sample that meets very strict stability criteria (sub-sample F).

In conclusion, the IFABI-R has evaluative and discriminative properties that make this instrument a useful instrument in the study of the quality of life of caregivers of children with asthma.

Conflict of interest

The authors have no conflict of interest to declare.

Funding

Healthcare Research Project PI11/02122, Instituto de Salud Carlos III, Ministry of Education and Competitiveness, Government of Spain.

Ethical disclosures

Confidentiality of data. The authors declare that no patient data appears in this article.

Right to privacy and informed consent. The authors declare that no patient data appears in this article.

Protection of human subjects and animals in research. The authors declare that no experiments were performed on humans or animals for this investigation.

Acknowledgements

Healthcare Research Project PI11/02122, Instituto de Salud Carlos III, Ministry of Education and Competitiveness, Government of Spain.

References

- Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three: a global synthesis. *Allergol Immunopathol (Madr)*. 2013;41:73–85.
- Carvajal Urueña I, García-Marcos L, Busquets Monge R, Morales Suárez-Varela M, García de Andoain N, Batlles garrido J, et al. Geographic variation in the prevalence of asthma symptoms in Spanish children and adolescents. International Study of Asthma and Allergies in Childhood (ISAAC) Phase 3, Spain. *Arch Bronconeumol*. 2005;41:659–66.
- National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Full report 2007. Available at: <http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf> [accessed 30.10.14].
- Global Initiative for Asthma. Global strategy for asthma management and prevention, revised 2014. Available at: <http://www.ginasthma.com> [accessed 30.10.14].
- Petsios KT, Priftis KN, Hatziaorou E, Tsanakas JN, Antonogeorgos G, Matziou VN. Determinants of quality of life in children with asthma. *Pediatr Pulmonol*. 2013;48:1171–80.
- Cano-Garcinuño A, Bercedo-Sanz A, Mora-Gandarillas I, Callén-Blecua MT, Castillo-Laita JA, Forns-Serrallonga D, et al. Association between quality of life in parents and components of asthma control in children. *J Asthma*. 2014;51:1089–95.
- Mandhane PJ, McGhan SL, Sharpe HM, Wong E, Hessel PA, Befus AD, et al. A child's asthma quality of life rating does not significantly influence management of their asthma. *Pediatr Pulmonol*. 2010;45:141–8.
- Klok T, Kaptein AA, Duiverman EJ, Brand PL. It's the adherence, stupid (that determines asthma control in preschool children)! *Eur Respir J*. 2014;43:783–91.
- Juniper EF, Guyatt GH, Ferrie DH, Ferrie PJ, Griffith LE, Townsed M. Measuring quality of life in the parents of children with asthma. *Qual Life Res*. 1996;5:27–34.
- Forns D, Prat R, Tauler E. Evaluation of quality of life among the caregivers of asthmatic children: the new IFABI-R questionnaire. *Allergol Immunopathol (Madr)*. 2011;39:32–8.
- Forns D, Prat R, Tauler E, Bosque M. Percepción de síntomas y limitación de actividades cotidianas en niños y adolescentes asmáticos. *Allergol Immunopathol (Madr)*. 2007;35 Suppl. 1:51.
- Bazán Velázquez GE, Forns Serrallonga D, Prat Santaolara R, Torres Velázquez LE, Ocaña Servín H, Paredes Rivera MP, et al. Validación del cuestionario Percepción parental de síntomas infantiles de asma en México. *Rev Inst Nal Enf Resp Mex*. 2008;21:169–80.
- Usherwood TP, Scrimgeour A, Barber JH. Questionnaire to measure perceived symptoms and disability in asthma. *Arch Dis Child*. 1990;65:779–81.
- Smilkenstein G. The family Apgar: a proposal of a family function test and its use by physicians. *J Fam Pract*. 1978;6:1231–9.
- Bellón Saameño JA, Delgado Sánchez A, Luna del Castillo JD, Lardelli Claret P. Validez y fiabilidad del cuestionario de función familiar Apgar-familiar. *Aten Primaria*. 1996;18:289–96.
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Series ATS/ERS Task Force: standardisation of lung function testing. Standardisation of spirometry. *Eur Respir J*. 2005;26:319–38.
- Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95 years age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40:1324–43.
- Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. *Psychol Bull*. 1979;86:420–8.

En el paciente polisensibilizado

Allergovac Poliplus



Crecemos en concentración Crecemos en beneficios



Dos tratamientos en uno

Máxima concentración de cada fuente alergénica sin dilución en la mezcla

FUENTE ALERGÉNICA 1



FUENTE ALERGÉNICA 2



100% de la concentración
de cada una de las fuentes
alergénicas



Comodidad para el paciente polisensibilizado



Ahorro para el paciente frente a vacunas individuales



Con cuantificación de alérgenos mayores¹⁻⁹

POSIBLES COMBINACIONES

- Gramíneas + Olea
- Gramíneas + Cupressus
- Gramíneas + Parietaria
- Cupressus + Olea
- Olea + Parietaria
- Cupressus + Parietaria
- Salsola + Gramíneas
- Salsola + Olea
- Salsola + Parietaria

- Platanus + Gramíneas

Próxima combinación

1. NOMBRE DEL MEDICAMENTO: ALLERGOVAC POLIPLUS. **2. COMPOSICIÓN CUALITATIVA Y CUANTITATIVA:** Extractos alergénicos estandarizados biológicamente en unidades TPU/ml, polimerizados con glutaraldehído, purificados por ultrafiltración y analizados por técnicas inmunológicas. Se presentan adsorbidos en hidróxido de aluminio y suspendidos en solución salina fisiológica fenolada. Excipiente(s) con efecto conocido: Este medicamento contiene menos de 1 mmol (23 mg) de sodio por dosis, por lo que se considera esencialmente "exento de sodio". Para consultar la lista completa de excipientes ver sección 6.1. **3. FORMA FARMACÉUTICA:** Suspensión estéril para inyección por vía subcutánea. **4. DATOS CLÍNICOS:** **4.1 Indicaciones terapéuticas:** Enfermedades alérgicas respiratorias mediadas por IgE y causadas por alérgenos, que cursan con rinitis, rinoconjuntivitis y asma bronquial. **4.2 Posología y forma de administración:** Posología: La iniciación consiste en el escalado progresivo de la dosis hasta alcanzar la dosis de mantenimiento. ALLERGOVAC POLIPLUS se puede administrar siguiendo dos pautas diferentes, la Pauta 1 día, en la que se llega a la dosis de mantenimiento el mismo día que se inicia el tratamiento, y la Pauta rápida, en la que se repite a intervalos mensuales hasta agotar el contenido de los viales 3 disponibles. **Pauta rápida:** el escalado se iniciará con la administración de 0,1 ml el primer día (día 1), 0,3 ml transcurrida una semana (día 8), y 0,5 ml al cabo de una nueva semana (día 15). Un mes después de esta última visita (día 45) se administrará 0,5 ml, repitiéndose esta misma dosis a intervalos mensuales hasta agotar el contenido de los viales 3 disponibles. **Forma de administración:** Previamente a la extracción de la dosis que corresponda administrar, el vial debe ser agitado suavemente. Deben emplearse jeringas tipo tuberculina de 1 ml graduadas en décimas de ml. Las agujas deben ser subcutáneas, de un calibre aproximado de 4 décimas de mm. Siendo un preparado multidosis, deben extremarse las precauciones para asegurar la esterilidad de las dosis siguientes. Se perforará el tapón con la jeringa dando la vuelta al vial y extrayendo el volumen correspondiente. La administración se realizará bajo la supervisión del especialista en hospital, ambulatorio o consulta médica. Las inyecciones subcutáneas deben realizarse en la cara exterior dorsal del brazo, en la línea media entre el hombro y el codo, alternando de brazo cada vez. **4.3 Contraindicaciones:** Hipersensibilidad a cualquiera de los excipientes incluidos en la sección 6.1. Trastornos del sistema inmunitario o neoplasias; asma severo incontrolable; enfermedades renales, hepáticas o hematológicas; tuberculosis activa; enfermedades en las que el uso de adrenalina esté contraindicado, como enfermedades coronarias o hipertensión arterial severa; tratamiento simultáneo con bloqueantes beta-adrenérgicos. No se debe desarrollar cualquier actividad física intensa tras la administración de una dosis. **4.4 Advertencias y precauciones de empleo:** ALLERGOVAC POLIPLUS debe administrarse bajo supervisión médica. En caso de fiebre superior a los 38,5 °C, se deberá posponer la administración de la vacuna hasta que dicha circunstancia se haya resuelto. La dermatitis alérgica severa puede verse agudizada durante este tratamiento. Si se interrumpe el tratamiento o el intervalo entre dosis ha sido mayor del recomendado, podría ser necesaria una modificación de la pauta recomendada. En caso de fuentes alergénicas polínicas, se podría considerar la modificación de los volúmenes de administración durante la polinización. ALLERGOVAC POLIPLUS sólo debe aplicarse en centros convenientemente dotados, que dispongan de medios inmediatamente accesibles que permitan proceder al tratamiento de un paciente que eventualmente sufra una reacción generalizada (urticaria, asma, shock anafiláctico, etc.), tales como adrenalina por vía intramuscular u otros. No deben ser administrados en ningún caso en el domicilio del paciente. Después de la aplicación de cada una de las dosis, el paciente permanecerá 30 minutos como mínimo en el centro donde se le haya administrado el preparado. Ante la aparición de cualquier reacción adversa, antes de proseguir con el tratamiento, consultar con el médico. **4.5 Interacción con otros medicamentos y otras formas de interacción:** La tolerancia del paciente a la inmunoterapia puede estar aumentada transitoriamente por el uso de medicamentos antialérgicos (antihistamínicos, corticoides, etc.), por tanto si la administración de éstos se interrumpe, debe valorarse la posibilidad de reducir la dosis de ALLERGOVAC POLIPLUS en prevención de eventuales reacciones adversas. En el apartado 4.3 Contraindicaciones se hace referencia a los medicamentos que no deben ser administrados durante un posible tratamiento con POLIPLUS. **4.6 Fertilidad, embarazo y lactancia:** Embarazo: No se debe iniciar la administración de la inmunoterapia con vacunas alergénicas durante el embarazo. Si el embarazo se produce cuando el tratamiento ha llegado a la dosis de mantenimiento, no habiéndose presentado reacciones adversas de importancia, podrá continuarse. Lactancia: No se dispone de datos clínicos sobre la utilización de ALLERGOVAC POLIPLUS durante la lactancia. **Fertilidad:** No hay datos clínicos al respecto de la fertilidad para el uso de ALLERGOVAC POLIPLUS. **4.7 Efectos sobre la capacidad de conducir y utilizar máquinas:** La influencia de ALLERGOVAC POLIPLUS sobre la capacidad para conducir y utilizar máquinas es nula o insignificante. **4.8 Reacciones adversas:** Se pueden presentar reacciones locales consistentes en enrojecimiento, prurito e induración en el lugar de la inyección que son normales, siempre y cuando no excedan del tamaño de 5 cm de diámetro. Las reacciones sistémicas, que consisten en la aparición de síntomas producidos por la inmunoterapia fuera del lugar de inyección, pueden incluir manifestaciones como la rinitis, la urticaria, el angioedema, el asma y la anafilaxia, pudiendo aparecer de manera temprana a los pocos minutos o bien varias horas después de la inyección subcutánea. Las reacciones locales grandes (superiores a 5-10 cm de diámetro) pueden requerir la aplicación de frío local, antihistamínicos orales y/o corticoides locales o sistémicos. Las sistémicas pueden precisar la administración de adrenalina, antihistamínicos, corticosteroides, fluidoterapia y broncodilatadores. Si la reacción sistémica es tardía, el paciente debe informar a su médico o acudir al servicio médico más cercano. **Notificación de sospechas de reacciones adversas.** Es importante notificar las sospechas de reacciones adversas al medicamento tras su autorización. Ello permite una supervisión continuada de la relación beneficio/riesgo del medicamento. Se invita a los profesionales sanitarios a notificar las sospechas de reacciones adversas a través del sistema nacional de notificación, incluido en el Sistema Español de Farmacovigilancia de Medicamentos de Uso Humano: www.notificar.madrid.es. **4.9 Sobredosis:** En caso de una sobredosis accidental o de una aplicación incorrecta del tratamiento, pueden presentarse cuadros de reacciones adversas, algunas de ellas severas, como las descritas en el apartado 4.8. En estas circunstancias es necesaria una evaluación clínica inmediata, así como el tratamiento de dichos cuadros con la medicación correspondiente a cada caso. El médico deberá evaluar la necesidad de suspender el tratamiento de forma permanente o bien establecer las modificaciones de la pauta que considere oportunas. **5. PROPIEDADES FARMACOLÓGICAS:** **5.1 Propiedades farmacodinámicas:** Grupo farmacoterapéutico: Alergenos. Código ATC: V01A. **5.2 Propiedades farmacocinéticas:** Alergenos polimerizados y adsorbidos en hidróxido de aluminio que reducen su capacidad de unión a IgE. El tratamiento consiste en una preparación retard en la que los alérgenos previamente polimerizados son liberados lentamente después de la inyección. **6. DATOS FARMACÉUTICOS:** **6.1 Lista de excipientes:** Fenol, hidróxido de aluminio, cloruro de sodio, hidróxido de sodio y agua para inyección. **6.2 Incompatibilidades:** No procede. **6.3 Período de validez:** 12 meses. **6.4 Precauciones especiales de conservación:** Conservar en nevera (entre 2 °C y 8 °C). Evitar exposiciones prolongadas a focos de calor y cambios bruscos de temperatura. No congelar. **6.5 Naturaleza y contenido del envase:** Envase conteniendo 1 o 2 viales 3 con 2,5 ml cada uno. **6.6 Precauciones especiales de eliminación y otras manipulaciones:** La eliminación del medicamento no utilizado y de todos los materiales que hayan estado en contacto con él, se realizará de acuerdo a la normativa local. **7. TITULAR DE LA AUTORIZACIÓN DE COMERCIALIZACIÓN:** Responsable de la fabricación: Bial Industrial Farmacéutica S.A., Parque Científico y Tecnológico de Bizkaia, Edificio 401, 48170 Zamudio (Vizcaya), España. **8. FECHA DE LA REVISIÓN DEL TEXTO:** 03/2015. **PRESENTACIONES:** ALLERGOVAC POLIPLUS envase con 1 o 2 viales 3 con 2,5 ml cada uno. **CONDICIONES DE PRESCRIPCIÓN Y DISPENSACIÓN:** Medicamento sujeto a prescripción médica. Financiado por el Sistema Nacional de Salud.

BIBLIOGRAFÍA: 1. Arilla MC, Ibarrola I, García R, De la Hoz B, Martínez A. Quantification of the major allergen from cypress (*Cupressus arizonica*) pollen, Cup a 1, by monoclonal antibody based ELISA. *Int Arch Allergy Immunol* 2004; 134: 10-16. 2. Arilla MC, Ibarrola I, Martínez A, Asturias JA. Characterization of Olea europaea pollen extracts for clinical use. *Allergy* 2009; 64 (Suppl. 90): 272. 3. Arilla MC, Ibarrola I, Brena S, Martínez A, Colás C, Asturias JA. The Russian thistle (*Salsola kali*) pollen major allergen, Sal k 1, can be quantified in allergenic extracts and airborne pollen. *Int Arch Allergy Immunol* 2010; 152:319-326. 4. Arilla MC, Ibarrola I, Eraso E, Aguirre M, Martínez A, Asturias JA. Quantification in mass units of group 1 grass allergens by a monoclonal antibody-based sandwich ELISA. *Clin Exp Allergy* 2001; 31:1271-1278. 5. Arilla MC, Ibarrola I, Martínez A, Asturias JA. Quantification of Ole e 9 content in O. europaea pollen extracts. *Allergy* 2008; 63 (Suppl. 88): 497. 6. Arilla MC, González-Rioja R, Ibarrola I, Mir A, Monteseirín J, Conde J, Martínez A, Asturias JA. A sensitive monoclonal antibody based ELISA to quantify Parietaria judaica major allergens, Par j 1 and Par j 2. *Clin Exp Allergy* 2006; 36: 87-93. 7. Arilla MC, Eraso E, Ibarrola I, Aljorta J, Martínez A, Asturias JA. Monoclonal antibody based method for measuring olive pollen major allergen Ole e 1. *Ann Allergy Asthma Immunol* 2002; 89: 83-89. 8. Arilla MC, Ibarrola I, Eraso E, Martínez A, Asturias JA. Inmunosensado para la cuantificación de Dac g 1 en extractos de polen. *Allergol Immunol Clin* 2002; 17: 231-237. 9. Arilla MC, Ibarrola I, Mir A, Monteseirín J, Conde J, Martínez A, Asturias JA. Development of a sandwich-type ELISA for measuring Pla a 1, the major allergen of Platanus acerifolia pollen. *Int Arch Allergy Immunol* 2005; 38:127-133.



Bial - ARISTEGUI

Bial Industrial Farmacéutica S.A.
Clara del Rey 31, 1ª Planta. 28002 MADRID
Parque Científico y Tecnológico de Bizkaia, Edificio 401
48170 Zamudio (Vizcaya), España
Tel.: 94 443 80 00 - FAX 94 443 80 16
e-mail: info.espana@bial.es